Table 1 |
|||
|
Characteristics of the subjects. |
|||
|
Asthma |
Healthy control |
p |
|
|
|
|||
|
n |
36 |
14 |
|
|
Gender (male/female) |
10/26 |
2/12 |
|
|
Age |
40 (18-68) |
37 (21-67) |
|
|
Atopy# |
22 |
5 |
|
|
Smoking (mean pack years) |
|||
|
Current |
9 (6) |
0 |
|
|
Previous |
3 (11) |
0 |
|
|
Use of inhaled corticosteroids (ICS) |
24 |
0 |
|
|
Daily dose of ICS |
541 ± 391 μg |
- |
|
|
ASA intolerance |
3 |
0 |
|
|
Use of ACE inhibitors |
5 |
0 |
|
|
Exhaled nitric oxide |
18.4 ± 15.0 |
14.6 ± 6.59 |
0.376 |
|
FEV1 (% from predicted)¶ |
90.0 (67-122) |
92.8 (78-110) |
0.418 |
|
Mean daily PEF variability (%) |
7.90 ± 5.75 |
- |
|
|
Needed rescue medication doses during pre-test week |
0.83 (0-4) |
- |
|
|
CDR Hypertonic saline coughs/(mOsm/kg) |
0.012 ± 0.010 |
0 |
<0.001 |
|
CDR Hyperpnoea of dry air coughs/MVV% |
0.464 ± 0.514 |
0.011 ± 0.024 |
<0.001 |
|
|
|||
|
Age, FEV1 and needed rescue medication doses mean (range). # Atopy was assessed as ≥3 mm mean wheal diameter in the skin prick test to at least one common aeroallergen. Daily dose of ICS, exhaled NO, mean daily PEF variability and CDR (cough-to-dose ratio) mean ± SD. ¶ Reference values are those of Viljanen et al. [34] |
|||
|
Purokivi et al. Cough 2011 7:8 doi:10.1186/1745-9974-7-8 |
|||
